Lilly Snaps Up Calytrix in $1.5 Billion Rare Cancer Push
Eli Lilly is acquiring Calytrix Bio for up to $1.5 billion, adding a rare blood cancer specialist to its active 2026 biotech deal spree.
Eli Lilly is adding to what has already been a prolific streak of biotechnology company acquisitions this year, announcing on Monday that it is buying a stealthy start-up focused on medicines for rare blood cancers.
Eli Lilly is paying up to $1.5 billion to acquire Calytrix Bio, a Wellesley, Massachusetts-based biotech developing treatments for slow-growing malignancies known as myeloproliferative neoplasms. Calytrix did not disclose how much guaranteed cash is involved in the deal, saying only that the offer includes an upfront payment and subsequent payouts tied to certain unspecified clinical and regulatory milestones.
Calytrix is developing treatments for myelofibrosis and essential thrombocythemia, both of which are forms of myeloproliferative neoplasms. These conditions occur when the body overproduces red blood cells, leading to bone marrow scarring, clots and other health problems. Existing treatments include blood transfusions and “JAK” inhibitor drugs such as Incyte’s Jakafi. Calytrix argues, however, that these therapies only manage symptoms and complications, leaving an opportunity for drugs that can precisely target disease-causing mutations.
Calytrix has developed a special type of double-barrelled antibody that it believes could change the course of disease for people whose condition is driven by mutations in a gene called “CALR.” When this mutation occurs, a particular cell-surface protein emerges that can be precisely targeted while sparing healthy tissue. Calytrix is pursuing that approach with a “biparatopic” antibody, a drug that binds to two separate sites on the same protein. It did not provide additional details on the therapy or its targets.
“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms,” stated Brad Prosek, Calytrix’s President and CEO, in a statement. “We look forward to Lilly advancing the programme through the clinic and exploring its potential to benefit patients across the disease spectrum.”
The acquisition adds to a considerable run for Lilly, which has emerged as the biotech sector’s most prolific dealmaker in an active year for acquisitions. Including Monday’s purchase, Lilly has spent more than $30 billion this year on 15 company acquisitions, the majority of them involving privately held start-ups. The next-highest totals belong to GSK, Gilead Sciences and Novartis, each of which has bought three drug companies in 2026.
Source: Lilly adds to buyout streak with $1.5B purchase of startup Calytrix. [Accessed 16/11/2026] www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/